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Abstract
Background: Histone deacetylase (HDAC) is an enzyme that regulates chromatin structure and inflammatory gene
expression. In patients with chronic obstructive pulmonary disease (COPD), while accumulating evidence indicates
that the activity of HDAC is decreased in lung tissue alveolar macrophages, HDAC activity in peripheral
inflammatory cells has not yet been evaluated in detail.
Methods: HDAC activities in peripheral blood mononuclear cells (PBMC) were investigated in patients with stable
COPD (n = 26), non-smoking controls (n = 13), and smoking controls (n = 10), respectively. HDAC activity was
measured using an HDAC Activity/Inhibitor Screening Assay Kit. Serum interleukine-8 (CXCL8) levels were
determined by ELISA techniques. Lung function test was carried out according to the ATS/ERS guidelines.
Results: Compared with healthy non-smokers, HDAC activity in the PBMCs of COPD patients was decreased by 40%
(13.06 ± 5.95 vs. 21.39 ± 4.92 (μM/μg), p < 0.001). In patients with COPD, HDAC activity was negatively correlated to
smoke intensity (r = -0.867, p < 0.001). In COPD patients who had smoked for more than 40 pack-years, HDAC activity
in PBMC was 40% lower than that in COPD patients who had smoked fewer than 40 pack-years.
Moreover, serum CXCL8 levels in patients with COPD were significantly higher than that in controls and were
negatively correlated to HDAC activities.
Conclusion: In patients with COPD, HDAC activity in the PBMCs is lower than that in healthy controls. The
reduction of HDAC activity may be associated with smoking exposure through inflammatory pathways.
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Introduction
Chronic obstructive pulmonary disease (COPD) is not
only an airway disease but also a systemic disorder that
involves systemic inflammatory manifestations [1,2]. In
COPD, systemic inflammation is evidenced by increased
levels of inflammatory cytokines in circulation even
when the condition is stable [3-6]. Inflammatory cells
such as macrophages and monocytes have been well
known to be involved in pulmonary and systemic
inflammation, but their exact role in the pathogenesis of
COPD has not yet been clarified [7-10].
Histone acetylase (HAT) and histone deacetylase
(HDAC) are families of enzymes that regulate chromatin
structure and inflammatory gene expression. Compared
to healthy controls, COPD patients showed low HDAC
activity in their alveolar macrophages [11,12]. This is
believed to be associated with the severity of limitations
in air flow. Recently it was found that corticosteroids
can synergistically stimulate CXCL8 (a proinflammatory
cytokine) production from macrophages [13] and
enhances the release of CXCL8 from plasmacytoid den-
dritic cells [14]. However, no further data has been col-
lected to demonstrate whether peripheral HDAC activity,
e.g. that in peripheral blood mononuclear cells (PBMCs),
is decreased as well. If HDAC activity is reduced periph-
erally, then it is interesting to know whether the HDAC
activity is related to smoke or even relevant to limitations
in air flow.
In this study, we compared HDAC activity in PBMCs
from COPD patients and healthy controls. We further
explored the associations of HDAC activity with smok-
ing and inflammatory marker.
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Subjects
Study subjects were recruited at Renmin Hospital of
Wuhan University in Wuhan, China. Criteria for recruit-
ing patients with COPD included the following: 1) Diag-
nosis of COPD according to GOLD criteria with a ratio
of post-bronchodilator forced expiratory volume in 1 sec-
ond (FEV1)/forced vital capacity (FVC) ≤70% [13]; 2) age
over or equal to 40 years; 3) cigarette smoke intake equal
to or greater than 10 pack-years; and 4) chest CT scan
indicating emphysematous abnormalities, such as barrel
chest or central-lobular or pan-lobular emphysema.
Exclusion criteria were as follows: 1) The presence of any
other structural or functional lung disease, such as a past
or current diagnosis of allergic rhinitis or atopy; 2)
respiratory tract infection or exacerbation of COPD
exacerbation no more than 6 weeks prior to screening; 3)
asthma; 4) blood eosinophil count > 600 cell/mm
3;5 )
hospitalization for an acute COPD exacerbation no more
than 3 months prior to screening; 6) clinically significant
respiratory disease other than COPD; and 7) unstable
cardiac condition. Inhaled salbutamol was permitted as
needed so long as it was discontinued 24 hours prior to
each study visit. Inhaled corticosteroids and oral sus-
tained-release theophyllines were also permitted. Oral or
parenteral corticosteroids at maximal doses equivalent to
10 mg/day of prednisone or 20 mg every other day were
permitted. Patients who were already on oxygen therapy
were included so long as their intake was < 15 hours per
day and had been stable for at least 4 weeks prior to
screening.
Recruitment criteria for control smokers were as fol-
lows: Voluntary cigarette intake of at least 10 pack-years
with no history of lung disease or unstable cardiac condi-
tions. The study also included healthy individuals with
no history of smoking.
The studies were conducted in accordance with the
Declaration of Helsinki, International Conference on
Harmonisation Good Clinical Practice Guidelines. The
study was approved by the Ethics Committee of the
Wuhan University School of Medicine. All participants
agreed to participate in this study and provided written
informed consent before participating in the study.
Study design
We performed a prospective study with two visits on
separate days. At visit 1, subjects provided written
informed consent and were asked about their demo-
graphic information, respiratory symptoms by trained
research nurse or doctor using standardized respiratory
questionnaire. Physical examinations were performed at
this time. FEV1 and FEV1 reversibility were tested.
Smoking history information was also collected and
quantified as pack-years. After visit 1, participants were
asked to stop using all drugs and treatment. At visit 2,
scheduled at least 2-4 days after visit 1, subjects under-
went a spirometry post-bronchodilator test. Peripheral
venous blood (20 ml) was extracted from each patient
with a heparin syringe. The blood samples were isolated
by density centrifugation within 4 hours, then PBMCs
were stored at -70°C and serum were stored at -20°C, all
samples were prepared less 3 month before analysis.
Spirometry
Spirometry tests were conducted according to ATS/ERS
standardization guidelines for the performance of spirome-
try and assessment of lung volume using body plethysmo-
graphy [15]. Typical practice in our laboratory incorporates
quality control measures, including daily instrument cali-
bration and review of study quality by a supervising techni-
cian and physician prior to interpretation. Flow-volume
curves, FVC, relative FVC, FEV1, relative FEV1, and FEV1/
FVC were measured using a spirometer (Vmax 229,
Sensor-Medics, U.S.) and the best volume of the three
manoeuvres was selected for data analysis. Data was
expressed as the percentage of predicted normal values.
Lung function test was conducted after inhaling 200 μg
sabutamol (Glaxo Welcome, Chongqing, China).
Separation of human PBMCs
Venous blood (20 ml) collected from each subject’s ulnar
vein was diluted 1:1 with sterile Hank’sB a l a n c e dS a l tS o l u -
tion. PBMCs were isolated from the blood by density cen-
trifugation as described previously [16]. Diluted venous
blood (40 mL) was added on top of 20 ml of LymphoPrep
(density, 1.077 g/ml) (Projen Biotechnik, Germany) and
centrifuged for 20 minutes at 1,100 g at room tempera-
ture. The interface that contained the PBMC was collected
and washed twice with phosphate-buffered saline (PBS).
Cells were pelleted by centrifugation at 250 g for 8 min
and stained with Kimura dye for determination of total
cell number. Cell viability, as determined by trypan blue,
was uniformly ≥95%.
Direct extraction of histones from human PBMC
Histones were extracted from PBMC nuclei using HCl and
H2SO4 at 4°C following the method described by Ito [17].
Cells were microcentrifuged for 5 min and the cell pellets
were extracted with ice-cold lysis buffer (10 mM Tris·HCl,
pH 6.5/50 mM sodium bisulfite, 1% Triton X-100·10 mM
MgCl2/8.6% sucrose complete protease inhibitor mixture
(Roche Molecular Biochemicals) for 20 min at 4°C. The
pellet was washed repeatedly in buffer until the superna-
tant was cleared (centrifuged at 7,500 g × 5 min after each
wash). The nuclear pellet was washed in nuclear wash buf-
fer (10mMTris·HCl/13mMEDTA, pH 7.4) and resus-
pended in 50 μl of 0.2 M HCl and 0.2 M H2SO4.T h e
supernatant was mixed with 1 ml of ice-cold acetone and
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for 10 min, washed with acetone, dried, and diluted in dis-
tilled water. The protein concentrations of the histone-
containing supernatant were determined using a Bradford
protein assay kit (Bio-Rad).
Measurement of HDAC activity in PBMCs
HDAC activity in PBMC nuclear extracts was assessed
using an HDAC Activity/Inhibitor Screening Assay Kit
(Cayman, U.S.). An acetylated lysine substrate is incubated
with samples with HDAC activity. Deacetylation sensitizes
the substrate such that treatment with the HDAC develo-
per in the second step releases a fluorescent product. The
assay was performed exactly as recommended by the man-
ufacturer. Fluorescence signal was detected at 460 nm
using a fluorometric plate reader.
Analysis of CXCL8 levels in peripheral blood
Serum levels of interleukine-8 (CXCL8) were measured by
sandwich ELISA (Jingmei Biotech Co., Ltd., Shenzhen,
China) according to the manufacturer’si n s t r u c t i o n s .
Statistics
Data are expressed as means ± SE (Medians). Analysis of
variance was performed with the use of the non-para-
metric Kruskal-Wallis test. When the result was signifi-
cant, the Mann-Whitney U test was performed for
comparisons between groups (SPSS software version 15.0).
Correlation coefficients were calculated with the use of
Spearman’sr a n km e t h o d .P < 0.05 was considered to




Demographic data from all participants are presented in
Table 1. There were 23 healthy volunteers, among them
10 were habitual cigarette smokers and 13 were never
smokers. All 26 patients with COPD were habitual cigar-
ette smokers, of whom 7 were in GOLD stage 1, 8 in
G O L Ds t a g e2 ,8i ns t a g e3 ,a n d3i ns t a g e4( T a b l e1 , 2 ) .
No significant differences were observed between COPD
cases and controls in terms of age, height, and body
weight.
HDAC activity in PBMCs of COPD patients
HDAC activity in the PBMCs of COPD patients was sig-
nificantly decreased by 40% as compared to that in
healthy non-smokers (13.06 ± 5.95 vs. 21.39 ± 4.92 μM/
μg, p < 0.001). HDAC activity in PBMCs of healthy smo-
kers was also 40% lower than that observed in healthy
non-smokers (12.50 ± 4.27 vs. 21.39 ± 4.92 μM/μg, p <
0.001). (Figure 1)
Relationship between HDAC activity in PBMCs and
cigarettes smoking levels
HDAC activity in PBMCs was decreased as the smoking
levels (pack-years) increased, (Figure 2). In COPD
patients who were heavy smokers (≥ 40 pack-years),
HDAC activity in the PBMCs was 40% lower than that
Table 1 Baseline characteristics of the Study Subjects *
COPD group (n = 26) Healthy smoker
group (n = 10)
Healthy non-smoker
group (n = 13)
Height (cm) 164.54 ± 6.08 (165) 167.56 ± 6.60 (170) 169.54 ± 5.94 (169)
Age (year) 63.50 ± 19.75 (71) 52.70 ± 12.33 (51) 54.85 ± 11.42 (54)
Weight (kg) 63.31 ± 11.61 (61) 68.50 ± 14.49 (74) 68.00 ± 7.92 (70)
FVC_volume (L) 2.68 ± 0.92 (2.36) 4.09 ± 0.68 (4.01) 3.92 ± 0.72 (3.82)
FVC% 86 ± 20 (89) 121 ± 21 (116) 113 ± 21 (114)
FEV1_volum (L) 1.35 ± 0.63 (1.20) 3.34 ± 0.55 (3.38) 3.00 ± 0.77 (2.90)
FEV1% 55 ± 19 (50) 124 ± 21 (115) 109 ± 27 (112)
FEV1/FVC% 50 ± 12 (50) 82 ± 5 (80) 76 ± 6 (79)
Smoking(pack-years) 33.46 ± 17.19(30) 36.5 ± 18.11(35) 0
Sex (M/F) 21/5 8/2 9/4
White blood cell counts in peripheral blood(10
9) 7.12 ± 2.56(6.95) 7.06 ± 2.44(6.90) 6.88 ± 2.66(6.73)
Medication (No)
Oral corticosteroid 0 0 0
Inhaled corticosteroid 3 0 0
Short-acting beta-adrenergic-receptor agonist 4 0 0
Theophyline 0 0 0
Oxygen 1 0 0
*COPD denotes chronic obstructive pulmonary disease, FEV 1 forced expiratory volume in one second, FVC forced vital capacity, pack-years the number of
cigarettes smoked per day, or 20 cigarettes, multiplied by the number of years of smoking. Plus-minus values are means ± SE(Mediam)
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(Figure 3).
CXCL8 levels in peripheral blood
Higher serum CXCL8 levels were found in stable COPD
patients than in non-smoker controls. In addition,
increased serum CXCL8 levels were negatively corre-
lated to HDAC activity in PBMCs (r = -0.468, p < 0.01)
(Figure 4). Patients who smoked more than 40 pack-
years had higher serum CXCL8 levels than those who
had smoke less than 40 pack-years.
Table 2 Baseline characteristics of the COPD subgroup Subjects *
Smoke ≧ 40 pack-year(n = 13) Smoke < 40 pack-year(n = 23)
Height (cm) 163.00 ± 6.02(163.00) 166.52 ± 6.17(167.00)
Age (year) 68.31 ± 11.11(74.00) 56.09 ± 20.50(61.00)
Weight (kg) 66.08 ± 12.70(60.00) 64.00 ± 12.58(65.00)
FVC_volume (L) 2.73 ± 0.96(2.36) 3.26 ± 1.10(3.38)
FVC% 92 ± 22(95) 98 ± 27(100)
FEV1_volum (L) 1.62 ± 0.84(1.32) 2.06 ± 1.20(1.43)
FEV1% 70 ± 31(63) 76 ± 41(59)
FEV1/FVC% 45.80 ± 30.02(30.00) 48.21 ± 24.77(32.40)
Smoking(pack-years) 53.85 ± 7.68(60.00) 23.26 ± 9.37(30.00)
Sex (M/F) 11/2 20/3
Medication (No)
Oral corticosteroid 0 0
Inhaled corticosteroid 2 1
Short-acting beta-adrenergic-receptor agonist 2 2
Theophylline 0 0
Oxygen 1 0
*COPD denotes chronic obstructive pulmonary disease, FEV 1 forced expiratory volume in one second, FVC forced vital capacity, pack-years the number of
cigarettes smoked per day, or 20 cigarettes, multiplied by the number of years of smoking. Plus-minus values are means ± SE(Mediam)
Figure 1 HDAC activities of PBMC (μM/μg) between smokers
and non-smokers. HDAC activities of PBMC in both smokers with
COPD and smokers without COPD were significantly lower than that
in non-smokers. (* p < 0.01 compared to Non-smokers).
Figure 2 Relationship between HDAC activity and smoking
exposure levels. In heavy-smoking COPD patients (≥ 40 pack-
years), HDAC activity in the PBMCs was lower than that in patients
smoked fewer than 40 pack-years.
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No correlation was found between the severity of airway
obstruction and HDAC activity or serum CXCL8 level
(all p > 0.05).(Table 3).
Discussion
In the present study, we show that HDAC activity in
PBMCs was lower in stable COPD patients than that in
h e a l t h yn o n - s m o k e rc o n t r o l s .T h ed e c r e a s eo fH D A C
activity was significantly associated with smoking expo-
sure levels and serum CXCL8 concentrations, suggesting
that HDAC activity in PBMC may be modified by sys-
temic inflammation and smoking quantities.
Our findings are consistent with previous observations
that systemic inflammation is implicated in the develop-
ment of COPD [2].The origins of the systemic inflam-
mation in patients with COPD are not entirely clear. It
is likely that the systemic inflammation is a consequence
of spillover of inflammatory mediators from the lungs to
the systemic compartment [18-20]. Decreased HDAC
activity was observed in bronchial biopsies and alveolar
macrophage from subjects with COPD [12]. Together
with our observation, it is clear that HDAC activity was
decreased not only in the lung tissue and alveolar cells
but also in the PBMCs. Interestingly, in heavy-smoking
COPD patients (≥ 40 pack-years), HDAC activity in the
PBMCs was 40% lower than that in patients smoked
fewer than 40 pack-years.
Figure 3 Relationship between smoking levels and serum
CXCL8 concentrations in COPD smokers. At 40 pack-years,
increases in blood CXCL8 levels became statistically significant.
Figure 4 Correlation of smoking quantity with HDAC activity in COPD patients. When smoking quantity reaches 40 pack-years, HDAC
activity decreased significantly (* p < 0.01 compared to Non-smokers).
Table 3 Correlation of HDAC activity in PBMC with Lung











HDAC r 0.164 0.234 0.249 0.294 0.057
p . 0.423 0.249 0.221 0.144 0.783
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inflammation plays a critical role in the pathogenesis of
COPD [21]. For instance, sustained inflammation exists
in ex-smokers as well as in current smokers in COPD
[22-24]. Our results suggest that the number of cigar-
ettes smoked over time may be related to serum levels
of CXCL8, a marker of systemic inflammation. Our
results also show that HDAC activity in PBMCs is
decreased as the cigarette smoking levels (pack-years)
over 40, suggesting heavy smokers seem to have a far
more significant reduction of HDAC activities and
increased CXCL8 than light smokers. This observation
may partially explain why sustained inflammation exists
in ex-smokers as well as in current smokers in COPD
Our results are also in agreement with prior reports
that serum CXCL8 levels are increased in stable COPD
patients [3,25], supporting previous findings that COPD
is a systemic inflammatory disease. Furthermore, we
found that increased serum CXCL8 levels were nega-
tively correlated with HDAC activities in PBMCs, sug-
gesting that HDAC has a role in systemic inflammation
of stable COPD patients.
In this study, no correlation was found between the
severity of airway obstruction and HDAC activity or
serum CXCL8 level. This suggests that systemic inflam-
mation may not directly contribute to COPD develop-
ment but by cooperation with other biological pathways.
There are a few limitations in this study. Firstly, the
sample size was relatively small. Thus we were not able
to conduct stratified analysis. Second, HAT activity was
not analyzed to determine whether the decreased
HDAC activity was related to HAT activity. Third, we
did not analyze local lung inflammation simultaneously.
Thus, the relationship between systemic inflammation
and lung local inflammation cannot be defined. Finally,
because all the COPD patients in our district are almost
smokers, we couldn’t enroll COPD patients due to occu-
pational exposures, including organic and inorganic
dusts and chemical agents and fumes, which will give
more information about the HDAC activity of PBMC in
non-smoking COPD patients.
Conclusion
In conclusion, our findings suggest that smoking is asso-
ciated with decreased HDAC activity and high levels of
CXCL8 in patients with COPD. Further studies includ-
ing more individuals are required to confirm our results
and to explore detailed mechanisms underlying the
associations between HDAC activities and smoking
levels in COPD.
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